Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Danazol (Primary) ; Ruxolitinib (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Planned End Date changed from 1 Nov 2014 to 1 Jul 2017.